Clinical Trials Logo
  1. Home
  2. Juvenile Dermatomyositis
  3. NCT03432455
  4. Details
NCT03432455 Clinical Trial

Incidence and Prevalence of Juvenile Dermatomyositis

Juvenile Dermatomyositis Clinical Trial

Official title:
Incidence and Prevalence of Juvenile Dermatomyositis in Alsace Between 2000 to 2015

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT03432455
Other study ID # 6784
Secondary ID
Status Recruiting
Phase N/A
First received February 7, 2018
Last updated February 7, 2018
Start date February 7, 2018
Est. completion date January 2019

Study information
Verified date February 2018
Source University Hospital, Strasbourg, France
Contact Dan LIPSKER, MD, PhD
Phone 33.3.88.11.61.79
Email dan.lipsker@chru-strasbourg.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a descriptive, retrospective, multi-center, cross-sectional and observational epidemiological study of incidence and prevalence of juvenile dermatomyositis in Alsace from 2000 to 2015. Alsace is a French region with a low migratory flow

Recruitment information / eligibility
Status Recruiting
Enrollment 22
Est. completion date January 2019
Est. primary completion date January 2019
Accepts healthy volunteers
Gender All
Age group N/A to 16 Years
Eligibility Inclusion Criteria:

- Age under 16 years

- Have a dermatomyositis according to the diagnostic criteria of Bohan and Peter of 1975

Exclusion Criteria:

- Refusal to participate in the study

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
France Service de Dermatologie Strasbourg

Sponsors (1)
Lead Sponsor Collaborator
University Hospital, Strasbourg, France

Country where clinical trial is conducted

France, 

Outcome
Type Measure Description Time frame Safety issue
Primary Identify incident and prevalent cases of juvenile dermatomyositis according to Bohan and Peter's criteria at january 1st, 2016 via capture/recapture strategy The period from from January 1st, 2000 to December 31st, 2015 will be examined
See also
  Status Clinical Trial Phase
Recruiting NCT05545839 - Transition to Adulthood Through Coaching and Empowerment in Rheumatology N/A
Recruiting NCT05524311 - Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis (MYOCIT) Phase 2
Recruiting NCT00059748 - Studies of the Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases Including Juvenile Dermatomyositis
Completed NCT00323960 - Five-year Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis Phase 3
Completed NCT02267005 - The Effect of Creatine Supplementation on Muscle Function in Childhood Myositis N/A
Completed NCT00106184 - Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM) Phase 2
Completed NCT02245841 - Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis Phase 4
Completed NCT03430388 - Yellow Fever Vaccine in Patients With Rheumatic Diseases N/A
Recruiting NCT01217320 - Creatine Supplementation in Pediatric Rheumatology N/A
Completed NCT05509140 - Clinical Analysis of Juvenile Dermatomyositis Patients
Recruiting NCT01276470 - Environmental Risk Factors for the Anti-synthetase Syndrome
Recruiting NCT03433638 - Juvenile Dermatomyositis N/A
Completed NCT00815282 - Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Phase 4
Completed NCT01697254 - The CARRA Registry N/A